We envision a world where drug delivery is not just about administering medication but ensuring optimal bioavailability, tailored treatment, and patient-centric care. We aim to lead the global pharmaceutical industry by consistently pushing the boundaries of innovation, addressing critical healthcare challenges, and fostering partnerships that transform lives.
BioPhoria is revolutionizing pharmaceutical care with its pioneering drug delivery systems. As pioneers in the Ketamine industry, we introduced the worlds first dry powder inhalable Ketamine featuring BioPhoria Control™, our rapid onset, pH-target released, technology delivering up to 65% bioavailability.
Our patented microencapsulated and enteric coated formulation process is used to create commercialized inhalable and ingestible ketamine products allowing for up to 95% bioavailability, as well as for research in other Therapeutics, Psychedelics, and Alternative Medicines.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2023
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was BioPhoria founded?
BioPhoria was founded in 2023.
What industry is BioPhoria in?
BioPhoria operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is BioPhoria based?
BioPhoria is headquartered in San Diego, United States.
Find investors for your startup like BioPhoria
Gritt sends AI-personalised outreach to each investor — from your Gmail
